- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Biochemistry Research International
Volume 2012 (2012), Article ID 738274, 5 pages
Endometrial Cancer and Hypermethylation: Regulation of DNA and MicroRNA by Epigenetics
Department of Obstetrics and Gynecology, Keio University School of Medicine, Shinanomachi 35 Shinjuku-ku, Tokyo 160-8582, Japan
Received 31 October 2011; Accepted 2 February 2012
Academic Editor: Yong-yu Liu
Copyright © 2012 Kouji Banno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. Esteller, “Epigenetics in cancer,” New England Journal of Medicine, vol. 358, no. 11, pp. 1148–1159, 2008.
- S. A. Wajed, P. W. Laird, and T. R. DeMeester, “DNA methylation: an alternative pathway to cancer,” Annals of Surgery, vol. 234, no. 1, pp. 10–20, 2001.
- Y. Muraki, K. Banno, M. Yanokura et al., “Epigenetic DNA hypermethylation: clinical applications in endometrial cancer,” Oncology Reports, vol. 22, no. 5, pp. 967–972, 2009.
- A. Velasco, J. Pallares, M. Santacana et al., “Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma,” Human Pathology, vol. 42, no. 2, pp. 185–193, 2011.
- J. Pallares, A. Velasco, N. Eritja et al., “Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma,” Modern Pathology, vol. 21, no. 6, pp. 691–699, 2008.
- H. S. Kang, T. Baba, M. Mandai et al., “GPR54 is a target for suppression of metastasis in endometrial cancer,” Molecular Cancer Therapeutics, vol. 10, no. 4, pp. 580–590, 2011.
- T. Z. Yi, J. Guo, L. Zhou et al., “Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma,” Cancer Investigation, vol. 29, no. 1, pp. 86–92, 2011.
- S. B. Dewdney, B. J. Rimel, P. H. Thaker et al., “Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers,” Clinical Cancer Research, vol. 17, no. 8, pp. 2120–2129, 2011.
- A. Ignatov, J. Bischoff, T. Ignatov et al., “APC promoter hypermethylation is an early event in endometrial tumorigenesis,” Cancer Science, vol. 101, no. 2, pp. 321–327, 2010.
- A. Satoh, M. Toyota, F. Itoh et al., “Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer,” Cancer Research, vol. 63, no. 24, pp. 8606–8613, 2003.
- X. Wang, Y. Yang, C. Xu et al., “CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel,” International Journal of Gynecological Cancer, vol. 21, no. 6, pp. 996–1003, 2011.
- T. L. Lo, P. Yusoff, C. W. Fong et al., “The Ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer,” Cancer Research, vol. 64, no. 17, pp. 6127–6136, 2004.
- H. Sutterlüty, C. E. Mayer, U. Setinek et al., “Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms,” Molecular Cancer Research, vol. 5, no. 5, pp. 509–520, 2007.
- C. W. Fong, M. S. Chua, A. B. McKie et al., “Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma,” Cancer Research, vol. 66, no. 4, pp. 2048–2058, 2006.
- R. Holliday, “The inheritance of epigenetic defects,” Science, vol. 238, no. 4824, pp. 163–170, 1987.
- P. N. Schofield, J. A. Joyce, W. K. Lam et al., “Genomic imprinting and cancer; new paradigms in the genetics of neoplasia,” Toxicology Letters, vol. 120, no. 1–3, pp. 151–160, 2001.
- P. Peltomäki, “Lynch syndrome genes,” Familial Cancer, vol. 4, no. 3, pp. 227–232, 2005.
- E. Kondo, T. Furukawa, K. Yoshinaga et al., “Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability.,” International journal of oncology, vol. 17, no. 3, pp. 535–541, 2000.
- C. M. Suter, D. I. K. Martin, and R. L. Ward, “Germline epimutation of MLH1 in individuals with multiple cancers,” Nature Genetics, vol. 36, no. 5, pp. 497–501, 2004.
- M. P. Hitchins, J. J. L. Wong, G. Suthers et al., “Inheritance of a cancer-associated MLH1 germ-line epimutation,” New England Journal of Medicine, vol. 356, no. 7, pp. 697–705, 2007.
- A. Goel, T. P. Nguyen, H. C. E. Leung et al., “De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one,” International Journal of Cancer, vol. 128, no. 4, pp. 869–878, 2011.
- T. L. Chan, S. T. Yuen, C. K. Kong et al., “Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer,” Nature Genetics, vol. 38, no. 10, pp. 1178–1183, 2006.
- B. T. F. van der Gun, L. J. Melchers, M. H. Ruiters, L. F. M. H. de Leij, P. M. J. McLaughlin, and M. G. Rots, “EpCAM in carcinogenesis: the good, the bad or the ugly,” Carcinogenesis, vol. 31, no. 11, pp. 1913–1921, 2010.
- M. J. L. Ligtenberg, R. P. Kuiper, T. L. Chan et al., “Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1,” Nature Genetics, vol. 41, no. 1, pp. 112–117, 2009.
- K. I. Kozaki, I. Imoto, S. Mogi, K. Omura, and J. Inazawa, “Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer,” Cancer Research, vol. 68, no. 7, pp. 2094–2105, 2008.
- M. Furuta, K. I. Kozaki, S. Tanaka, S. Arii, I. Imoto, and J. Inazawa, “miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma,” Carcinogenesis, vol. 31, no. 5, pp. 766–776, 2009.
- J. Pierson, B. Hostager, R. Fan, and R. Vibhakar, “Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma,” Journal of Neuro-Oncology, vol. 90, no. 1, pp. 1–7, 2008.
- Y. Saito, J. M. Friedman, Y. Chihara, G. Egger, J. C. Chuang, and G. Liang, “Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells,” Biochemical and Biophysical Research Communications, vol. 379, no. 3, pp. 726–731, 2009.
- H. Nakano, T. Miyazawa, K. Kinoshita, Y. Yamada, and T. Yoshida, “Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-XLin colorectal cancer cells,” International Journal of Cancer, vol. 127, no. 5, pp. 1072–1080, 2010.
- Y. W. Huang, J. C. Liu, D. E. Deatherage et al., “Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer,” Cancer Research, vol. 69, no. 23, pp. 9038–9046, 2009.
- T. Tsuruta, K. I. Kozaki, A. Uesugi et al., “miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer,” Cancer Research, vol. 71, no. 20, pp. 6450–6462, 2011.
- D. J. P. M. Stumpel, D. Schotte, E. A. M. Lange-Turenhout et al., “Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale,” Leukemia, vol. 25, no. 3, pp. 429–439, 2011.
- Y. Chen, Y. Song, Z. Wang et al., “Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance,” Journal of Gastrointestinal Surgery, vol. 14, no. 7, pp. 1170–1179, 2010.
- C. Braconi, N. Huang, and T. Patel, “Microrna-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes,” Hepatology, vol. 51, no. 3, pp. 881–890, 2010.
- H. Z. Chen, S. Y. Tsai, and G. Leone, “Emerging roles of E2Fs in cancer: an exit from cell cycle control,” Nature Reviews Cancer, vol. 9, no. 11, pp. 785–797, 2009.
- L. Trusolino, A. Bertotti, and P. M. Comoglio, “MET signalling: principles and functions in development, organ regeneration and cancer,” Nature Reviews Molecular Cell Biology, vol. 11, no. 12, pp. 834–848, 2010.
- D. Roulin, Y. Cerantola, A. Dormond-Meuwly, N. Demartines, and O. Dormond, “Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo,” Molecular Cancer, vol. 9, article no. 57, 2010.
- D. A. Guertin, D. M. Stevens, M. Saitoh et al., “mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice,” Cancer Cell, vol. 15, no. 2, pp. 148–159, 2009.